{"symbol":"REGN","fiscalQuarter":"Q3-2022","reportDate":"2022-11-03","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2022","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.24%","keyNumbers":[{"metric":"EPS","actual":"$11.14","expected":"N/A","surprise":"+30.31%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They noted ongoing investments in research and development.","There was an emphasis on maintaining a strong pipeline for future growth."],"summary":"Overall, management expressed confidence in their product lineup and future prospects. However, they did not provide specific guidance for the upcoming quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates better-than-expected profitability, which is a positive sign for investors. However, the stock's slight decline of 0.24% suggests that investors may have been looking for more detailed guidance or revenue figures. The lack of revenue data and forward guidance could lead to uncertainty in the market moving forward.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2022 earnings: EPS beat by 30.31%. Stock down 0.24%. Full breakdown."}}